HC Wainwright Has Pessimistic Outlook of SLDB Q2 Earnings

Solid Biosciences Inc. (NASDAQ:SLDB) – Equities research analysts at HC Wainwright reduced their Q2 2026 earnings per share estimates for Solid Biosciences in a research report issued on Wednesday, June 3rd. HC Wainwright analyst A. He now expects that the company will post earnings per share of ($0.41) for the quarter, down from their prior estimate of ($0.35). HC Wainwright currently has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Solid Biosciences’ current full-year earnings is ($1.81) per share. HC Wainwright also issued estimates for Solid Biosciences’ Q3 2026 earnings at ($0.41) EPS, Q4 2026 earnings at ($0.41) EPS, FY2026 earnings at ($1.72) EPS, Q1 2027 earnings at ($0.42) EPS, Q2 2027 earnings at ($0.43) EPS, Q3 2027 earnings at ($0.44) EPS, Q4 2027 earnings at ($0.43) EPS, FY2027 earnings at ($1.72) EPS, FY2028 earnings at ($1.33) EPS and FY2029 earnings at $0.26 EPS.

A number of other analysts also recently issued reports on SLDB. Weiss Ratings reissued a “sell (d-)” rating on shares of Solid Biosciences in a research report on Tuesday, April 21st. Piper Sandler reissued an “overweight” rating and issued a $18.00 target price (up from $17.00) on shares of Solid Biosciences in a research report on Wednesday, May 13th. Wedbush decreased their target price on Solid Biosciences from $17.00 to $16.00 and set an “outperform” rating for the company in a research report on Wednesday, May 13th. JPMorgan Chase & Co. raised their target price on Solid Biosciences from $11.00 to $12.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 25th. Finally, Guggenheim assumed coverage on Solid Biosciences in a research report on Friday, March 20th. They issued a “buy” rating and a $26.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Solid Biosciences currently has an average rating of “Moderate Buy” and an average price target of $16.82.

Solid Biosciences Price Performance

NASDAQ:SLDB opened at $7.24 on Friday. The business has a fifty day simple moving average of $7.42 and a two-hundred day simple moving average of $6.51. Solid Biosciences has a 1 year low of $3.68 and a 1 year high of $8.87. The company has a market capitalization of $712.78 million, a P/E ratio of -3.71 and a beta of 2.43.

Solid Biosciences (NASDAQ:SLDB) last released its earnings results on Tuesday, May 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.12).

Institutional Investors Weigh In On Solid Biosciences

Several large investors have recently added to or reduced their stakes in the business. MetLife Investment Management LLC boosted its stake in Solid Biosciences by 10.4% during the fourth quarter. MetLife Investment Management LLC now owns 33,202 shares of the company’s stock valued at $187,000 after buying an additional 3,124 shares during the period. Quantum Private Wealth LLC boosted its stake in Solid Biosciences by 3.9% during the third quarter. Quantum Private Wealth LLC now owns 94,231 shares of the company’s stock valued at $581,000 after buying an additional 3,500 shares during the period. Legal & General Group Plc boosted its stake in Solid Biosciences by 208.6% during the second quarter. Legal & General Group Plc now owns 6,011 shares of the company’s stock valued at $29,000 after buying an additional 4,063 shares during the period. Intech Investment Management LLC boosted its stake in Solid Biosciences by 15.2% during the fourth quarter. Intech Investment Management LLC now owns 34,485 shares of the company’s stock valued at $194,000 after buying an additional 4,539 shares during the period. Finally, Russell Investments Group Ltd. lifted its stake in Solid Biosciences by 142.0% during the third quarter. Russell Investments Group Ltd. now owns 10,211 shares of the company’s stock worth $63,000 after purchasing an additional 5,991 shares during the last quarter. Institutional investors own 81.46% of the company’s stock.

Trending Headlines about Solid Biosciences

Here are the key news stories impacting Solid Biosciences this week:

• Positive Sentiment: HC Wainwright raised its price target on Solid Biosciences to $25 and kept a Buy rating, reinforcing a bullish long-term view for reference.
• Neutral Sentiment: HC Wainwright’s updated forecasts still call for substantial losses in 2026-2028, though the firm expects the company to move toward profitability later in the decade.
• Negative Sentiment: The analyst lowered near-term EPS estimates for FY2026, FY2027, FY2028 and several quarterly periods, which could limit momentum in the stock.

Solid Biosciences Company Profile

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.